Last reviewed · How we verify
NCT05883657
Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation)
NA trial testing Condition 1 : Prototypes (816-v1) every weeks in Solar Lentigo in 80 participants. Status unknown.
12 December 2023
Quick facts
| Lead sponsor | Cryonove Pharma |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 10 June 2023 |
| Primary completion | 12 December 2023 |
| Estimated completion | 12 December 2023 |
| Sites | 1 location across South Africa |
Drugs / interventions tested
- Condition 1 : Prototypes (816-v1) every weeks
- Condition 2 : Prototypes (816-v1) every two weeks
Conditions studied
- Solar Lentigo — all drugs for Solar Lentigo →
- Senile Lentigo — all drugs for Senile Lentigo →
- Post Inflammatory Hyperpigmentation — all drugs for Post Inflammatory Hyperpigmentation →
Sponsor
Cryonove Pharma
Who can join
Adults 18 to 75, any sex, with Solar Lentigo or Senile Lentigo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CS5\_7 study aim to evaluate the tolerance and to adjust the mode of administration of two conditions of cryotherapy treatment applied on the brown spots of the face and hands with 1 prototype (816-v1). A brown spot is defined as solar or senile lentigo and post-inflammatory hyperpigmentation (PIH). The study will evaluate the following prototype : • Prototypes from (816-v1 201) to (816-v1 290)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05883657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Cryonove Pharma trials
Trials by the same sponsor.
- NCT06361251 — Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyt · NA · completed
- NCT05886010 — Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and S · NA · unknown
- NCT05625815 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots. · NA · completed
- NCT05793619 — Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment o · NA · completed
- NCT05600049 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05883657 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cryonove Pharma
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing